Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"The combination of DMPI's VAL-083 and radiation therapy showed an immediate survival benefit in glioblastoma multiforme." (10/30/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Brandon Primack Moreá>
Companies Commented On
- BioCryst Pharmaceuticals Inc.
- Dynavax Technologies Corp.
- Galectin Therapeutics Inc.
- Galmed Pharmaceuticals Ltd.
- Immune Pharmaceuticals Inc.
- NeoStem Inc.
- Pluristem Therapeutics Inc.
Vernon Bernardino is an analyst in MLV & Co.'s life sciences equity research department. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and immunotherapy companies that focus on treatment of cancer, infectious diseases and cell-based therapies targeting inflammatory disorders and vascular diseases. Bernardino brings more than 10 years of experience covering life sciences companies at various financial institutions, including Rodman & Renshaw, UBS and Dawson James. Earlier in his career, Bernardino was a buyside analyst at Nicholas Applegate Capital Management, and founded the strategic advisory group Oceros Advisors LP. Bernardino holds a bachelor's degree from Rutgers University and a master's degree in business administration (finance) from the University of San Diego.
Biotechs with Upside Possibilities Target Ebola and Liver Disease: MLV & Co.'s Vernon Bernardino (9/10/14) Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.
Not All Stem Cells Are Created Equal: Vernon Bernardino (10/3/13) Biotech companies are fiercely competing to create the newest and best miracle drugs using stem cell technologies. How can an investor spot the potentially victorious outliers amid the chaos of rival scientific claims? The failure rate of new product development in the only recently understood cell space is terrifying, but in this interview with The Life Sciences Report, analyst Vernon Bernardino of MLV & Co. reveals his formula for evaluating the strongest contenders. Bernardino also names five companies with products that may succeed in this new and competitive space.
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino Moreá>